These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7919225)

  • 1. Regulatory issues in clinical applications of cytokines and growth factors.
    Weiss KD; Siegel JP; Gerrard TL
    Prog Growth Factor Res; 1994; 5(2):213-22. PubMed ID: 7919225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA regulations for growth factors and related products.
    Chapekar MS; Gunter KC
    EXS; 1992; 61():471-8. PubMed ID: 1617242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An overview of drug development in the United States and current challenges.
    Moore SW
    South Med J; 2003 Dec; 96(12):1244-55; quiz 1256. PubMed ID: 14696877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Regulatory Evaluation of Vaccines for Human Use.
    Baylor NW
    Methods Mol Biol; 2016; 1404():773-787. PubMed ID: 27076337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and approval of vaccines in the United States.
    Botstein P
    Isr J Med Sci; 1986; 22(3-4):268-71. PubMed ID: 3528047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International Conference on Harmonisation; Electronic Transmission of Postmarket Individual Case Safety Reports for Drugs and Biologics, Excluding Vaccines; Availability of Food and Drug Administration Regional Implementation Specifications for ICH E2B(R3) Reporting to the Food and Drug Administration Adverse Event Reporting System. Notice of Availability.
    Food and Drug Administration, HHS
    Fed Regist; 2016 Jun; 81(121):40890-1. PubMed ID: 27373012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food and Drug Administration regulation and evaluation of vaccines.
    Marshall V; Baylor NW
    Pediatrics; 2011 May; 127 Suppl 1():S23-30. PubMed ID: 21502242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The drug approval process and the information it provides.
    Myers A; Moore SR
    Drug Intell Clin Pharm; 1987 Oct; 21(10):821-6. PubMed ID: 3322757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. United States Food and Drug Administration Regulation of Human Cells, Tissues, and Gene Therapies.
    Sanduja S; Lessey-Morillon L; Allen R; Wang X; Imperato G; Arcidiacono J
    Adv Exp Med Biol; 2023; 1430():71-89. PubMed ID: 37526843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current good manufacturing practice and investigational new drugs intended for use in clinical trials. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2008 Jul; 73(136):40453-63. PubMed ID: 18850678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eyes on the Prize: Decoding the Ophthalmic Product Regulations and Intricacies of the U.S. Food and Drug Administration Approval.
    Hirani K; Bansinath M; Mittal R; Lemos JRN; Adis E; Poojari P; Igoe JM; Soares MR; Bhattacharya S; Weiss RE
    J Ocul Pharmacol Ther; 2023 Oct; 39(8):572-582. PubMed ID: 37797226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of Food and Drug Administration regulation of drugs, biologics, and devices to be used for management of periodontal diseases.
    Tylenda CA; Weintraub M
    Ann Periodontol; 1997 Mar; 2(1):11-7. PubMed ID: 9151539
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics for inflammatory bowel disease: drug approval and monitoring in the United States.
    Tremaine WJ
    Gastroenterol Clin North Am; 2006 Dec; 35(4):735-41. PubMed ID: 17129810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No longer "if," but "when": the coming abbreviated approval pathway for follow-on biologics.
    Kelly JJ; David M
    Food Drug Law J; 2009; 64(1):115-48. PubMed ID: 19998743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of the U.S. Food and Drug Administration review process: clinical trial endpoints in oncology.
    McKee AE; Farrell AT; Pazdur R; Woodcock J
    Oncologist; 2010; 15 Suppl 1():13-8. PubMed ID: 20237212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.